Skip to main content

Table 2 Univariate Cox model analyses

From: Relationship between WBRT total dose, intracranial tumor control, and overall survival in NSCLC patients with brain metastases - a single-center retrospective analysis

Variables

OS

iPFS

HR

95%CI

pa

HR

95%CI

pa

WBRT (Gy)

 none

1.000

 

ref.

1.000

 

ref.

  < 30

1.418

(0.938–2.142)

0.098

1.713

(1.133–2.588)

0.011

 30–39

0.709

(0.540–0.933)

0.014

0.694

(0.533–0.904)

0.007

  ≥ 40

0.616

(0.483–0.785)

< 0.001

0.640

(0.506–0.809)

< 0.001

Local/boost RT (Gy)

 none

1.000

 

ref.

1.000

 

ref.

  < 50

0.722

(0.422–1.234)

ns

0.977

(0.608–1.572)

ns

 50–59

0.575

(0.436–0.759)

< 0.001

0.668

(0.515–0.866)

0.002

  ≥ 60

0.594

(0.427–0.825)

0.002

0.566

(0.409–0.783)

< 0.001

SRT

0.713

(0.365–1.391)

ns

0.645

(0.344–1.208)

ns

Female

0.761

(0.627–0.924)

0.006

0.754

(0.626–0.909)

0.003

CVD

0.970

(0.801–1.175)

ns

1.039

(0.863–1.250)

ns

Age (years)

  < 50

1.000

 

ref.

1.000

 

ref.

 50–59

1.051

(0.783–1.412)

ns

0.889

(0.673–1.174)

ns

  ≥ 60

1.363

(1.038–1.791)

0.052

1.169

(0.904–1.512)

ns

KPS

  < 70

1.000

 

ref.

1.000

 

ref.

 70–80

0.920

(0.718–1.178)

ns

0.918

(0.722–1.166)

ns

  ≥ 90

0.765

(0.610–0.958)

0.020

0.842

(0.676–1.047)

ns

NSCLC history (month)

  < 1

0.910

(0.710–1.167)

ns

1.023

(0.805–1.299)

ns

 1–6

1.153

(0.834–1.595)

ns

1.410

(1.030–1.931)

0.032

 6–12

1.107

(0.799–1.533)

ns

1.236

(0.972–1.693)

0.187

  > 12

1.000

 

ref.

1.000

 

ref.

BM lesion number

 1

1.000

 

ref.

1.000

 

ref.

 2–3

1.103

(0.833–1.461)

ns

1.053

(0.804–1.379)

ns

  ≥ 4

1.118

(0.907–1.377)

ns

1.099

(0.898–1.344)

ns

Extracranial met.

1.244

(0.988–1.565)

0.063

1.695

(1.356–2.120)

< 0.001

Brain stem met.

2.185

(1.226–3.896)

0.008

1.901

(1.069–3.381)

0.029

Meningeal met.

1.212

(0.853–1.723)

ns

1.501

(1.063–2.119)

0.021

Targeted therapy

0.492

(0.393–0.617)

< 0.001

0.597

(0.484–0.736)

< 0.001

Chemotherapy

0.612

(0.506–0.741)

< 0.001

0.791

(0.659–0.951)

0.013

BM resection

 none

1.000

 

ref.

1.000

 

ref.

 incomplete

0.786

(0.196–3.157)

ns

0.808

(0.201–3.245)

ns

 complete

0.882

(0.556–1.398)

ns

0.851

(0.549–1.320)

ns

Initial cTNM Stage IV

1.027

(0.829–1.271)

ns

1.106

(0.901–1.357)

ns

Lung tumor surgery

 none

1.000

 

ref.

1.000

 

ref.

 incomplete

0.842

(0.524–1.353)

ns

0.865

(0.546–1.372)

ns

 radical

0.917

(0.687–1.225)

ns

0.695

(0.527–0.916)

0.001

Adenocarcinoma

0.809

(0.659–0.993)

0.043

0.821

(0.672–1.002)

0.053

EGFR mutation

 neg.

1.000

 

ref.

1.000

 

ref.

 pos.

0.670

(0.484–0.927)

0.016

0.625

(0.460–0.850)

0.003

 no record

1.195

(0.931–1.534)

0.161

0.962

(0.756–1.226)

ns

ALK mutation

 neg.

1.000

 

ref.

 

1.000

 

ref.

 pos.

0.415

(0.118–1.458)

0.170

 

1.059

(0.351–3.191)

ns

 no record

1.006

(0.578–1.750)

ns

 

1.109

(0.663–1.857)

ns

  1. OS overall survival; iPFS intracranial progression-free survival; HR hazard ratio; 95%CI 95% confidence interval; WBRT whole brain radiotherapy; ref. reference; RT radiotherapy; ns not significant with p > 0.20; SRT stereotactic radiotherapy; CVD cardiovascular disease; BM brain metastasis; KPS Karnofsky Performance Score; NSCLC non-small cell lung cancer; met. Metastases; EGFR epidermal growth factor receptor; neg. Negative; pos. Positive; ALK anaplastic lymphoma kinase.
  2. a from the univariate Cox model analysis.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us